CPRX Relative Valuation
CPRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CPRX is overvalued; if below, it's undervalued.
Historical Valuation
Catalyst Pharmaceuticals Inc (CPRX) is now in the Fair zone, suggesting that its current forward PE ratio of 15.35 is considered Fairly compared with the five-year average of 14.22. The fair price of Catalyst Pharmaceuticals Inc (CPRX) is between 17.50 to 27.56 according to relative valuation methord.
Relative Value
Fair Zone
17.50-27.56
Current Price：22.67
Fair
15.35
PE
1Y
3Y
5Y
7.24
EV/EBITDA
Catalyst Pharmaceuticals Inc. (CPRX) has a current EV/EBITDA of 7.24. The 5-year average EV/EBITDA is 3.45. The thresholds are as follows: Strongly Undervalued below -5.29, Undervalued between -5.29 and -0.92, Fairly Valued between 7.81 and -0.92, Overvalued between 7.81 and 12.18, and Strongly Overvalued above 12.18. The current Forward EV/EBITDA of 7.24 falls within the Historic Trend Line -Fairly Valued range.
9.26
EV/EBIT
Catalyst Pharmaceuticals Inc. (CPRX) has a current EV/EBIT of 9.26. The 5-year average EV/EBIT is 8.92. The thresholds are as follows: Strongly Undervalued below 2.50, Undervalued between 2.50 and 5.71, Fairly Valued between 12.13 and 5.71, Overvalued between 12.13 and 15.33, and Strongly Overvalued above 15.33. The current Forward EV/EBIT of 9.26 falls within the Historic Trend Line -Fairly Valued range.
4.81
PS
Catalyst Pharmaceuticals Inc. (CPRX) has a current PS of 4.81. The 5-year average PS is 4.12. The thresholds are as follows: Strongly Undervalued below 2.50, Undervalued between 2.50 and 3.31, Fairly Valued between 4.93 and 3.31, Overvalued between 4.93 and 5.74, and Strongly Overvalued above 5.74. The current Forward PS of 4.81 falls within the Historic Trend Line -Fairly Valued range.
10.84
P/OCF
Catalyst Pharmaceuticals Inc. (CPRX) has a current P/OCF of 10.84. The 5-year average P/OCF is 10.50. The thresholds are as follows: Strongly Undervalued below 6.05, Undervalued between 6.05 and 8.27, Fairly Valued between 12.72 and 8.27, Overvalued between 12.72 and 14.95, and Strongly Overvalued above 14.95. The current Forward P/OCF of 10.84 falls within the Historic Trend Line -Fairly Valued range.
10.84
P/FCF
Catalyst Pharmaceuticals Inc. (CPRX) has a current P/FCF of 10.84. The 5-year average P/FCF is 10.86. The thresholds are as follows: Strongly Undervalued below 6.45, Undervalued between 6.45 and 8.66, Fairly Valued between 13.06 and 8.66, Overvalued between 13.06 and 15.26, and Strongly Overvalued above 15.26. The current Forward P/FCF of 10.84 falls within the Historic Trend Line -Fairly Valued range.
Catalyst Pharmaceuticals Inc (CPRX) has a current Price-to-Book (P/B) ratio of 3.10. Compared to its 3-year average P/B ratio of 3.89 , the current P/B ratio is approximately -20.25% higher. Relative to its 5-year average P/B ratio of 3.84, the current P/B ratio is about -19.16% higher. Catalyst Pharmaceuticals Inc (CPRX) has a Forward Free Cash Flow (FCF) yield of approximately 8.24%. Compared to its 3-year average FCF yield of 4.25%, the current FCF yield is approximately 93.84% lower. Relative to its 5-year average FCF yield of 5.71% , the current FCF yield is about 44.47% lower.
3.10
P/B
Median3y
3.89
Median5y
3.84
8.24
FCF Yield
Median3y
4.25
Median5y
5.71
Competitors Valuation Multiple
The average P/S ratio for CPRX's competitors is 34.09, providing a benchmark for relative valuation. Catalyst Pharmaceuticals Inc Corp (CPRX) exhibits a P/S ratio of 4.81, which is -85.9% above the industry average. Given its robust revenue growth of 15.31%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CPRX increased by 0.71% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 128.70M to 148.39M.
The secondary factor is the Margin Expansion, contributed 4.31%to the performance.
Overall, the performance of CPRX in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
HUT
Hut 8 Corp
57.95USD
0.12%
BHC
Bausch Health Companies Inc
7.77USD
-1.65%
YELP
Yelp Inc
30.31USD
0.07%
AKR
Acadia Realty Trust
21.07USD
2.08%
MANU
Manchester United PLC
16.39USD
0.31%
PRGS
Progress Software Corp
42.08USD
-1.80%
OII
Oceaneering International Inc
26.9USD
4.75%
TBBK
Bancorp Inc
70.32USD
1.34%
MRUS
Merus NV
91USD
-7.69%
CON
Concentra Group Holdings Parent Inc
19.91USD
2.10%
Frequently Asked Questions
Is Catalyst Pharmaceuticals Inc (CPRX) currently overvalued or undervalued?
Catalyst Pharmaceuticals Inc (CPRX) is now in the Fair zone, suggesting that its current forward PE ratio of 15.35 is considered Fairly compared with the five-year average of 14.22. The fair price of Catalyst Pharmaceuticals Inc (CPRX) is between 17.50 to 27.56 according to relative valuation methord.
What is Catalyst Pharmaceuticals Inc (CPRX) fair value?
CPRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Catalyst Pharmaceuticals Inc (CPRX) is between 17.50 to 27.56 according to relative valuation methord.
How does CPRX's valuation metrics compare to the industry average?
The average P/S ratio for CPRX's competitors is 34.09, providing a benchmark for relative valuation. Catalyst Pharmaceuticals Inc Corp (CPRX) exhibits a P/S ratio of 4.81, which is -85.90% above the industry average. Given its robust revenue growth of 15.31%, this premium appears unsustainable.
What is the current P/B ratio for Catalyst Pharmaceuticals Inc (CPRX) as of Jan 08 2026?
As of Jan 08 2026, Catalyst Pharmaceuticals Inc (CPRX) has a P/B ratio of 3.10. This indicates that the market values CPRX at 3.10 times its book value.
What is the current FCF Yield for Catalyst Pharmaceuticals Inc (CPRX) as of Jan 08 2026?
As of Jan 08 2026, Catalyst Pharmaceuticals Inc (CPRX) has a FCF Yield of 8.24%. This means that for every dollar of Catalyst Pharmaceuticals Inc’s market capitalization, the company generates 8.24 cents in free cash flow.
What is the current Forward P/E ratio for Catalyst Pharmaceuticals Inc (CPRX) as of Jan 08 2026?
As of Jan 08 2026, Catalyst Pharmaceuticals Inc (CPRX) has a Forward P/E ratio of 15.35. This means the market is willing to pay $15.35 for every dollar of Catalyst Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Catalyst Pharmaceuticals Inc (CPRX) as of Jan 08 2026?
As of Jan 08 2026, Catalyst Pharmaceuticals Inc (CPRX) has a Forward P/S ratio of 4.81. This means the market is valuing CPRX at $4.81 for every dollar of expected revenue over the next 12 months.